

Global Remicade (Infliximab) Monoclonal Antibody Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

<https://marketpublishers.com/r/GC4F1EAF3EAEEN.html>

Date: June 2023

Pages: 74

Price: US\$ 3,480.00 (Single User License)

ID: GC4F1EAF3EAEEN

Abstracts

According to our (Global Info Research) latest study, the global Remicade (Infliximab) Monoclonal Antibody market size was valued at USD 2623.8 million in 2022 and is forecast to a readjusted size of USD 3781.3 million by 2029 with a CAGR of 5.4% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The Remicade (Infliximab) monoclonal antibody market is driven by several factors. One of the primary drivers is the high prevalence of chronic autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, and psoriasis, which require targeted immunotherapy for effective management. Remicade, as a monoclonal antibody, has demonstrated significant efficacy in treating these conditions by specifically targeting and inhibiting tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation. Additionally, the increasing adoption of biologic therapies, including monoclonal antibodies, in clinical practice has fueled the demand for Remicade. The proven clinical efficacy, long-term safety profile, and established therapeutic outcomes have contributed to its market growth. Moreover, the expanding patient pool, coupled with the rising awareness and diagnosis rates of autoimmune diseases, has created a greater demand for targeted biologic treatments like Remicade. Furthermore, the presence of robust research and development activities aimed at developing novel monoclonal antibodies and exploring new indications for Remicade continues to drive market growth. Overall, the Remicade monoclonal antibody market is driven by the high prevalence of autoimmune diseases, increasing adoption of biologic therapies, established clinical efficacy, expanding patient pool, and ongoing research and development efforts.

Infliximab is a monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Avsola, Flixabi, Inflectra, Remicade, Renflexis.

This report is a detailed and comprehensive analysis for global Remicade (Infliximab) Monoclonal Antibody market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Remicade (Infliximab) Monoclonal Antibody market size and forecasts, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Remicade (Infliximab) Monoclonal Antibody market size and forecasts by region and country, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Remicade (Infliximab) Monoclonal Antibody market size and forecasts, by Type and by Application, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Remicade (Infliximab) Monoclonal Antibody market shares of main players, shipments in revenue (\$ Million), sales quantity (K Units), and ASP (US\$/Unit), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Remicade (Infliximab) Monoclonal Antibody

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Remicade (Infliximab) Monoclonal Antibody market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include J & J, Pfizer, Organon and Amgen, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market Segmentation

Remicade (Infliximab) Monoclonal Antibody market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Brand

Biosimilar

Market segment by Application

Ankylosing Spondylitis

Rheumatoid Arthritis

Crohn's Disease

Other

Major players covered

J & J

Pfizer

Organon

Amgen

Market segment by region, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Remicade (Infliximab) Monoclonal Antibody product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Remicade (Infliximab) Monoclonal Antibody, with price, sales, revenue and global market share of Remicade (Infliximab) Monoclonal Antibody from 2018 to 2023.

Chapter 3, the Remicade (Infliximab) Monoclonal Antibody competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Remicade (Infliximab) Monoclonal Antibody breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022. and Remicade (Infliximab) Monoclonal Antibody market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.

Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.

Chapter 13, the key raw materials and key suppliers, and industry chain of Remicade (Infliximab) Monoclonal Antibody.

Chapter 14 and 15, to describe Remicade (Infliximab) Monoclonal Antibody sales channel, distributors, customers, research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope of Remicade (Infliximab) Monoclonal Antibody

1.2 Market Estimation Caveats and Base Year

1.3 Market Analysis by Type

1.3.1 Overview: Global Remicade (Infliximab) Monoclonal Antibody Consumption Value by Type: 2018 Versus 2022 Versus 2029

1.3.2 Brand

1.3.3 Biosimilar

1.4 Market Analysis by Application

1.4.1 Overview: Global Remicade (Infliximab) Monoclonal Antibody Consumption Value by Application: 2018 Versus 2022 Versus 2029

1.4.2 Ankylosing Spondylitis

1.4.3 Rheumatoid Arthritis

1.4.4 Crohn's Disease

1.4.5 Other

1.5 Global Remicade (Infliximab) Monoclonal Antibody Market Size & Forecast

1.5.1 Global Remicade (Infliximab) Monoclonal Antibody Consumption Value (2018 & 2022 & 2029)

1.5.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Quantity (2018-2029)

1.5.3 Global Remicade (Infliximab) Monoclonal Antibody Average Price (2018-2029)

2 MANUFACTURERS PROFILES

2.1 J & J

2.1.1 J & J Details

2.1.2 J & J Major Business

2.1.3 J & J Remicade (Infliximab) Monoclonal Antibody Product and Services

2.1.4 J & J Remicade (Infliximab) Monoclonal Antibody Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)

2.1.5 J & J Recent Developments/Updates

2.2 Pfizer

2.2.1 Pfizer Details

2.2.2 Pfizer Major Business

2.2.3 Pfizer Remicade (Infliximab) Monoclonal Antibody Product and Services

2.2.4 Pfizer Remicade (Infliximab) Monoclonal Antibody Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)

2.2.5 Pfizer Recent Developments/Updates

2.3 Organon

2.3.1 Organon Details

2.3.2 Organon Major Business

2.3.3 Organon Remicade (Infliximab) Monoclonal Antibody Product and Services

2.3.4 Organon Remicade (Infliximab) Monoclonal Antibody Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)

2.3.5 Organon Recent Developments/Updates

2.4 Amgen

2.4.1 Amgen Details

2.4.2 Amgen Major Business

2.4.3 Amgen Remicade (Infliximab) Monoclonal Antibody Product and Services

2.4.4 Amgen Remicade (Infliximab) Monoclonal Antibody Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)

2.4.5 Amgen Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: REMICADE (INFLIXIMAB) MONOCLONAL ANTIBODY BY MANUFACTURER

3.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Manufacturer (2018-2023)

3.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Manufacturer (2018-2023)

3.3 Global Remicade (Infliximab) Monoclonal Antibody Average Price by Manufacturer (2018-2023)

3.4 Market Share Analysis (2022)

3.4.1 Producer Shipments of Remicade (Infliximab) Monoclonal Antibody by Manufacturer Revenue (\$MM) and Market Share (%): 2022

3.4.2 Top 3 Remicade (Infliximab) Monoclonal Antibody Manufacturer Market Share in 2022

3.4.2 Top 6 Remicade (Infliximab) Monoclonal Antibody Manufacturer Market Share in 2022

3.5 Remicade (Infliximab) Monoclonal Antibody Market: Overall Company Footprint Analysis

3.5.1 Remicade (Infliximab) Monoclonal Antibody Market: Region Footprint

3.5.2 Remicade (Infliximab) Monoclonal Antibody Market: Company Product Type Footprint

3.5.3 Remicade (Infliximab) Monoclonal Antibody Market: Company Product Application Footprint

- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

- 4.1 Global Remicade (Infliximab) Monoclonal Antibody Market Size by Region
 - 4.1.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Region (2018-2029)
 - 4.1.2 Global Remicade (Infliximab) Monoclonal Antibody Consumption Value by Region (2018-2029)
 - 4.1.3 Global Remicade (Infliximab) Monoclonal Antibody Average Price by Region (2018-2029)
- 4.2 North America Remicade (Infliximab) Monoclonal Antibody Consumption Value (2018-2029)
- 4.3 Europe Remicade (Infliximab) Monoclonal Antibody Consumption Value (2018-2029)
- 4.4 Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Consumption Value (2018-2029)
- 4.5 South America Remicade (Infliximab) Monoclonal Antibody Consumption Value (2018-2029)
- 4.6 Middle East and Africa Remicade (Infliximab) Monoclonal Antibody Consumption Value (2018-2029)

5 MARKET SEGMENT BY TYPE

- 5.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2018-2029)
- 5.2 Global Remicade (Infliximab) Monoclonal Antibody Consumption Value by Type (2018-2029)
- 5.3 Global Remicade (Infliximab) Monoclonal Antibody Average Price by Type (2018-2029)

6 MARKET SEGMENT BY APPLICATION

- 6.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2018-2029)
- 6.2 Global Remicade (Infliximab) Monoclonal Antibody Consumption Value by Application (2018-2029)
- 6.3 Global Remicade (Infliximab) Monoclonal Antibody Average Price by Application

(2018-2029)

7 NORTH AMERICA

7.1 North America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2018-2029)

7.2 North America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2018-2029)

7.3 North America Remicade (Infliximab) Monoclonal Antibody Market Size by Country

7.3.1 North America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Country (2018-2029)

7.3.2 North America Remicade (Infliximab) Monoclonal Antibody Consumption Value by Country (2018-2029)

7.3.3 United States Market Size and Forecast (2018-2029)

7.3.4 Canada Market Size and Forecast (2018-2029)

7.3.5 Mexico Market Size and Forecast (2018-2029)

8 EUROPE

8.1 Europe Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2018-2029)

8.2 Europe Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2018-2029)

8.3 Europe Remicade (Infliximab) Monoclonal Antibody Market Size by Country

8.3.1 Europe Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Country (2018-2029)

8.3.2 Europe Remicade (Infliximab) Monoclonal Antibody Consumption Value by Country (2018-2029)

8.3.3 Germany Market Size and Forecast (2018-2029)

8.3.4 France Market Size and Forecast (2018-2029)

8.3.5 United Kingdom Market Size and Forecast (2018-2029)

8.3.6 Russia Market Size and Forecast (2018-2029)

8.3.7 Italy Market Size and Forecast (2018-2029)

9 ASIA-PACIFIC

9.1 Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2018-2029)

9.2 Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Sales Quantity by

Application (2018-2029)

9.3 Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Market Size by Region

9.3.1 Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Region (2018-2029)

9.3.2 Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Consumption Value by Region (2018-2029)

9.3.3 China Market Size and Forecast (2018-2029)

9.3.4 Japan Market Size and Forecast (2018-2029)

9.3.5 Korea Market Size and Forecast (2018-2029)

9.3.6 India Market Size and Forecast (2018-2029)

9.3.7 Southeast Asia Market Size and Forecast (2018-2029)

9.3.8 Australia Market Size and Forecast (2018-2029)

10 SOUTH AMERICA

10.1 South America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2018-2029)

10.2 South America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2018-2029)

10.3 South America Remicade (Infliximab) Monoclonal Antibody Market Size by Country

10.3.1 South America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Country (2018-2029)

10.3.2 South America Remicade (Infliximab) Monoclonal Antibody Consumption Value by Country (2018-2029)

10.3.3 Brazil Market Size and Forecast (2018-2029)

10.3.4 Argentina Market Size and Forecast (2018-2029)

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2018-2029)

11.2 Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2018-2029)

11.3 Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Market Size by Country

11.3.1 Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Country (2018-2029)

11.3.2 Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Consumption Value by Country (2018-2029)

- 11.3.3 Turkey Market Size and Forecast (2018-2029)
- 11.3.4 Egypt Market Size and Forecast (2018-2029)
- 11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
- 11.3.6 South Africa Market Size and Forecast (2018-2029)

12 MARKET DYNAMICS

- 12.1 Remicade (Infliximab) Monoclonal Antibody Market Drivers
- 12.2 Remicade (Infliximab) Monoclonal Antibody Market Restraints
- 12.3 Remicade (Infliximab) Monoclonal Antibody Trends Analysis
- 12.4 Porters Five Forces Analysis
 - 12.4.1 Threat of New Entrants
 - 12.4.2 Bargaining Power of Suppliers
 - 12.4.3 Bargaining Power of Buyers
 - 12.4.4 Threat of Substitutes
 - 12.4.5 Competitive Rivalry
- 12.5 Influence of COVID-19 and Russia-Ukraine War
 - 12.5.1 Influence of COVID-19
 - 12.5.2 Influence of Russia-Ukraine War

13 RAW MATERIAL AND INDUSTRY CHAIN

- 13.1 Raw Material of Remicade (Infliximab) Monoclonal Antibody and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Remicade (Infliximab) Monoclonal Antibody
- 13.3 Remicade (Infliximab) Monoclonal Antibody Production Process
- 13.4 Remicade (Infliximab) Monoclonal Antibody Industrial Chain

14 SHIPMENTS BY DISTRIBUTION CHANNEL

- 14.1 Sales Channel
 - 14.1.1 Direct to End-User
 - 14.1.2 Distributors
- 14.2 Remicade (Infliximab) Monoclonal Antibody Typical Distributors
- 14.3 Remicade (Infliximab) Monoclonal Antibody Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

16.1 Methodology

16.2 Research Process and Data Source

16.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Remicade (Infliximab) Monoclonal Antibody Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Table 2. Global Remicade (Infliximab) Monoclonal Antibody Consumption Value by Application, (USD Million), 2018 & 2022 & 2029

Table 3. J & J Basic Information, Manufacturing Base and Competitors

Table 4. J & J Major Business

Table 5. J & J Remicade (Infliximab) Monoclonal Antibody Product and Services

Table 6. J & J Remicade (Infliximab) Monoclonal Antibody Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 7. J & J Recent Developments/Updates

Table 8. Pfizer Basic Information, Manufacturing Base and Competitors

Table 9. Pfizer Major Business

Table 10. Pfizer Remicade (Infliximab) Monoclonal Antibody Product and Services

Table 11. Pfizer Remicade (Infliximab) Monoclonal Antibody Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 12. Pfizer Recent Developments/Updates

Table 13. Organon Basic Information, Manufacturing Base and Competitors

Table 14. Organon Major Business

Table 15. Organon Remicade (Infliximab) Monoclonal Antibody Product and Services

Table 16. Organon Remicade (Infliximab) Monoclonal Antibody Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 17. Organon Recent Developments/Updates

Table 18. Amgen Basic Information, Manufacturing Base and Competitors

Table 19. Amgen Major Business

Table 20. Amgen Remicade (Infliximab) Monoclonal Antibody Product and Services

Table 21. Amgen Remicade (Infliximab) Monoclonal Antibody Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 22. Amgen Recent Developments/Updates

Table 23. Global Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Manufacturer (2018-2023) & (K Units)

Table 24. Global Remicade (Infliximab) Monoclonal Antibody Revenue by Manufacturer

(2018-2023) & (USD Million)

Table 25. Global Remicade (Infliximab) Monoclonal Antibody Average Price by Manufacturer (2018-2023) & (US\$/Unit)

Table 26. Market Position of Manufacturers in Remicade (Infliximab) Monoclonal Antibody, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022

Table 27. Head Office and Remicade (Infliximab) Monoclonal Antibody Production Site of Key Manufacturer

Table 28. Remicade (Infliximab) Monoclonal Antibody Market: Company Product Type Footprint

Table 29. Remicade (Infliximab) Monoclonal Antibody Market: Company Product Application Footprint

Table 30. Remicade (Infliximab) Monoclonal Antibody New Market Entrants and Barriers to Market Entry

Table 31. Remicade (Infliximab) Monoclonal Antibody Mergers, Acquisition, Agreements, and Collaborations

Table 32. Global Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Region (2018-2023) & (K Units)

Table 33. Global Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Region (2024-2029) & (K Units)

Table 34. Global Remicade (Infliximab) Monoclonal Antibody Consumption Value by Region (2018-2023) & (USD Million)

Table 35. Global Remicade (Infliximab) Monoclonal Antibody Consumption Value by Region (2024-2029) & (USD Million)

Table 36. Global Remicade (Infliximab) Monoclonal Antibody Average Price by Region (2018-2023) & (US\$/Unit)

Table 37. Global Remicade (Infliximab) Monoclonal Antibody Average Price by Region (2024-2029) & (US\$/Unit)

Table 38. Global Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2018-2023) & (K Units)

Table 39. Global Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2024-2029) & (K Units)

Table 40. Global Remicade (Infliximab) Monoclonal Antibody Consumption Value by Type (2018-2023) & (USD Million)

Table 41. Global Remicade (Infliximab) Monoclonal Antibody Consumption Value by Type (2024-2029) & (USD Million)

Table 42. Global Remicade (Infliximab) Monoclonal Antibody Average Price by Type (2018-2023) & (US\$/Unit)

Table 43. Global Remicade (Infliximab) Monoclonal Antibody Average Price by Type (2024-2029) & (US\$/Unit)

Table 44. Global Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2018-2023) & (K Units)

Table 45. Global Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2024-2029) & (K Units)

Table 46. Global Remicade (Infliximab) Monoclonal Antibody Consumption Value by Application (2018-2023) & (USD Million)

Table 47. Global Remicade (Infliximab) Monoclonal Antibody Consumption Value by Application (2024-2029) & (USD Million)

Table 48. Global Remicade (Infliximab) Monoclonal Antibody Average Price by Application (2018-2023) & (US\$/Unit)

Table 49. Global Remicade (Infliximab) Monoclonal Antibody Average Price by Application (2024-2029) & (US\$/Unit)

Table 50. North America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2018-2023) & (K Units)

Table 51. North America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2024-2029) & (K Units)

Table 52. North America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2018-2023) & (K Units)

Table 53. North America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2024-2029) & (K Units)

Table 54. North America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Country (2018-2023) & (K Units)

Table 55. North America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Country (2024-2029) & (K Units)

Table 56. North America Remicade (Infliximab) Monoclonal Antibody Consumption Value by Country (2018-2023) & (USD Million)

Table 57. North America Remicade (Infliximab) Monoclonal Antibody Consumption Value by Country (2024-2029) & (USD Million)

Table 58. Europe Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2018-2023) & (K Units)

Table 59. Europe Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2024-2029) & (K Units)

Table 60. Europe Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2018-2023) & (K Units)

Table 61. Europe Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2024-2029) & (K Units)

Table 62. Europe Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Country (2018-2023) & (K Units)

Table 63. Europe Remicade (Infliximab) Monoclonal Antibody Sales Quantity by

Country (2024-2029) & (K Units)

Table 64. Europe Remicade (Infliximab) Monoclonal Antibody Consumption Value by Country (2018-2023) & (USD Million)

Table 65. Europe Remicade (Infliximab) Monoclonal Antibody Consumption Value by Country (2024-2029) & (USD Million)

Table 66. Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2018-2023) & (K Units)

Table 67. Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2024-2029) & (K Units)

Table 68. Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2018-2023) & (K Units)

Table 69. Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2024-2029) & (K Units)

Table 70. Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Region (2018-2023) & (K Units)

Table 71. Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Region (2024-2029) & (K Units)

Table 72. Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Consumption Value by Region (2018-2023) & (USD Million)

Table 73. Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Consumption Value by Region (2024-2029) & (USD Million)

Table 74. South America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2018-2023) & (K Units)

Table 75. South America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2024-2029) & (K Units)

Table 76. South America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2018-2023) & (K Units)

Table 77. South America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2024-2029) & (K Units)

Table 78. South America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Country (2018-2023) & (K Units)

Table 79. South America Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Country (2024-2029) & (K Units)

Table 80. South America Remicade (Infliximab) Monoclonal Antibody Consumption Value by Country (2018-2023) & (USD Million)

Table 81. South America Remicade (Infliximab) Monoclonal Antibody Consumption Value by Country (2024-2029) & (USD Million)

Table 82. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2018-2023) & (K Units)

Table 83. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Type (2024-2029) & (K Units)

Table 84. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2018-2023) & (K Units)

Table 85. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Application (2024-2029) & (K Units)

Table 86. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Region (2018-2023) & (K Units)

Table 87. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Quantity by Region (2024-2029) & (K Units)

Table 88. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Consumption Value by Region (2018-2023) & (USD Million)

Table 89. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Consumption Value by Region (2024-2029) & (USD Million)

Table 90. Remicade (Infliximab) Monoclonal Antibody Raw Material

Table 91. Key Manufacturers of Remicade (Infliximab) Monoclonal Antibody Raw Materials

Table 92. Remicade (Infliximab) Monoclonal Antibody Typical Distributors

Table 93. Remicade (Infliximab) Monoclonal Antibody Typical Customers

List Of Figures

LIST OF FIGURES

- Figure 1. Remicade (Infliximab) Monoclonal Antibody Picture
- Figure 2. Global Remicade (Infliximab) Monoclonal Antibody Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
- Figure 3. Global Remicade (Infliximab) Monoclonal Antibody Consumption Value Market Share by Type in 2022
- Figure 4. Brand Examples
- Figure 5. Biosimilar Examples
- Figure 6. Global Remicade (Infliximab) Monoclonal Antibody Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
- Figure 7. Global Remicade (Infliximab) Monoclonal Antibody Consumption Value Market Share by Application in 2022
- Figure 8. Ankylosing Spondylitis Examples
- Figure 9. Rheumatoid Arthritis Examples
- Figure 10. Crohn's Disease Examples
- Figure 11. Other Examples
- Figure 12. Global Remicade (Infliximab) Monoclonal Antibody Consumption Value, (USD Million): 2018 & 2022 & 2029
- Figure 13. Global Remicade (Infliximab) Monoclonal Antibody Consumption Value and Forecast (2018-2029) & (USD Million)
- Figure 14. Global Remicade (Infliximab) Monoclonal Antibody Sales Quantity (2018-2029) & (K Units)
- Figure 15. Global Remicade (Infliximab) Monoclonal Antibody Average Price (2018-2029) & (US\$/Unit)
- Figure 16. Global Remicade (Infliximab) Monoclonal Antibody Sales Quantity Market Share by Manufacturer in 2022
- Figure 17. Global Remicade (Infliximab) Monoclonal Antibody Consumption Value Market Share by Manufacturer in 2022
- Figure 18. Producer Shipments of Remicade (Infliximab) Monoclonal Antibody by Manufacturer Sales Quantity (\$MM) and Market Share (%): 2021
- Figure 19. Top 3 Remicade (Infliximab) Monoclonal Antibody Manufacturer (Consumption Value) Market Share in 2022
- Figure 20. Top 6 Remicade (Infliximab) Monoclonal Antibody Manufacturer (Consumption Value) Market Share in 2022
- Figure 21. Global Remicade (Infliximab) Monoclonal Antibody Sales Quantity Market Share by Region (2018-2029)

Figure 22. Global Remicade (Infliximab) Monoclonal Antibody Consumption Value Market Share by Region (2018-2029)

Figure 23. North America Remicade (Infliximab) Monoclonal Antibody Consumption Value (2018-2029) & (USD Million)

Figure 24. Europe Remicade (Infliximab) Monoclonal Antibody Consumption Value (2018-2029) & (USD Million)

Figure 25. Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Consumption Value (2018-2029) & (USD Million)

Figure 26. South America Remicade (Infliximab) Monoclonal Antibody Consumption Value (2018-2029) & (USD Million)

Figure 27. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Consumption Value (2018-2029) & (USD Million)

Figure 28. Global Remicade (Infliximab) Monoclonal Antibody Sales Quantity Market Share by Type (2018-2029)

Figure 29. Global Remicade (Infliximab) Monoclonal Antibody Consumption Value Market Share by Type (2018-2029)

Figure 30. Global Remicade (Infliximab) Monoclonal Antibody Average Price by Type (2018-2029) & (US\$/Unit)

Figure 31. Global Remicade (Infliximab) Monoclonal Antibody Sales Quantity Market Share by Application (2018-2029)

Figure 32. Global Remicade (Infliximab) Monoclonal Antibody Consumption Value Market Share by Application (2018-2029)

Figure 33. Global Remicade (Infliximab) Monoclonal Antibody Average Price by Application (2018-2029) & (US\$/Unit)

Figure 34. North America Remicade (Infliximab) Monoclonal Antibody Sales Quantity Market Share by Type (2018-2029)

Figure 35. North America Remicade (Infliximab) Monoclonal Antibody Sales Quantity Market Share by Application (2018-2029)

Figure 36. North America Remicade (Infliximab) Monoclonal Antibody Sales Quantity Market Share by Country (2018-2029)

Figure 37. North America Remicade (Infliximab) Monoclonal Antibody Consumption Value Market Share by Country (2018-2029)

Figure 38. United States Remicade (Infliximab) Monoclonal Antibody Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 39. Canada Remicade (Infliximab) Monoclonal Antibody Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 40. Mexico Remicade (Infliximab) Monoclonal Antibody Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 41. Europe Remicade (Infliximab) Monoclonal Antibody Sales Quantity Market

Share by Type (2018-2029)

Figure 42. Europe Remicade (Infliximab) Monoclonal Antibody Sales Quantity Market Share by Application (2018-2029)

Figure 43. Europe Remicade (Infliximab) Monoclonal Antibody Sales Quantity Market Share by Country (2018-2029)

Figure 44. Europe Remicade (Infliximab) Monoclonal Antibody Consumption Value Market Share by Country (2018-2029)

Figure 45. Germany Remicade (Infliximab) Monoclonal Antibody Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 46. France Remicade (Infliximab) Monoclonal Antibody Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 47. United Kingdom Remicade (Infliximab) Monoclonal Antibody Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 48. Russia Remicade (Infliximab) Monoclonal Antibody Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 49. Italy Remicade (Infliximab) Monoclonal Antibody Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 50. Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Sales Quantity Market Share by Type (2018-2029)

Figure 51. Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Sales Quantity Market Share by Application (2018-2029)

Figure 52. Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Sales Quantity Market Share by Region (2018-2029)

Figure 53. Asia-Pacific Remicade (Infliximab) Monoclonal Antibody Consumption Value Market Share by Region (2018-2029)

Figure 54. China Remicade (Infliximab) Monoclonal Antibody Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 55. Japan Remicade (Infliximab) Monoclonal Antibody Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 56. Korea Remicade (Infliximab) Monoclonal Antibody Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 57. India Remicade (Infliximab) Monoclonal Antibody Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 58. Southeast Asia Remicade (Infliximab) Monoclonal Antibody Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 59. Australia Remicade (Infliximab) Monoclonal Antibody Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 60. South America Remicade (Infliximab) Monoclonal Antibody Sales Quantity Market Share by Type (2018-2029)

Figure 61. South America Remicade (Infliximab) Monoclonal Antibody Sales Quantity Market Share by Application (2018-2029)

Figure 62. South America Remicade (Infliximab) Monoclonal Antibody Sales Quantity Market Share by Country (2018-2029)

Figure 63. South America Remicade (Infliximab) Monoclonal Antibody Consumption Value Market Share by Country (2018-2029)

Figure 64. Brazil Remicade (Infliximab) Monoclonal Antibody Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 65. Argentina Remicade (Infliximab) Monoclonal Antibody Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 66. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Quantity Market Share by Type (2018-2029)

Figure 67. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Quantity Market Share by Application (2018-2029)

Figure 68. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Quantity Market Share by Region (2018-2029)

Figure 69. Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Consumption Value Market Share by Region (2018-2029)

Figure 70. Turkey Remicade (Infliximab) Monoclonal Antibody Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 71. Egypt Remicade (Infliximab) Monoclonal Antibody Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 72. Saudi Arabia Remicade (Infliximab) Monoclonal Antibody Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 73. South Africa Remicade (Infliximab) Monoclonal Antibody Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 74. Remicade (Infliximab) Monoclonal Antibody Market Drivers

Figure 75. Remicade (Infliximab) Monoclonal Antibody Market Restraints

Figure 76. Remicade (Infliximab) Monoclonal Antibody Market Trends

Figure 77. Porters Five Forces Analysis

Figure 78. Manufacturing Cost Structure Analysis of Remicade (Infliximab) Monoclonal Antibody in 2022

Figure 79. Manufacturing Process Analysis of Remicade (Infliximab) Monoclonal Antibody

Figure 80. Remicade (Infliximab) Monoclonal Antibody Industrial Chain

Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors

Figure 82. Direct Channel Pros & Cons

Figure 83. Indirect Channel Pros & Cons

Figure 84. Methodology

Figure 85. Research Process and Data Source

I would like to order

Product name: Global Remicade (Infliximab) Monoclonal Antibody Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Product link: <https://marketpublishers.com/r/GC4F1EAF3EAEEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC4F1EAF3EAEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

